EVOLUTION AT MERCK - INVENTING FOR LIFE

KEYTRUDA: REPEATED OVERALL SURVIVAL BENEFITS IN MONOTHERAPY AND IN COMBINATION Ipi-Naive Melanoma, 2L Bladder, Any PD-L1 Any PD-L1 KEYNOTE-006 Pembro vs Ipi KEYNOTE-045 Pembro vs Chemo 2L+ NSCLC, TPS ≥50% KEYNOTE-010 Pembro vs Docetaxel 2L+ NSCLC, TPS ≥1% KEYNOTE-010 Pembro vs Docetaxel 1L NSCLC, TPS ≥50% KEYNOTE-024 Pembro vs Chemo 1L RCC, Any PD-L1 KEYNOTE-426 Pembro + Axitinib vs Sunitinib 10 20 ; 24 10 30 60 Months No. al Risk 9 4D 50 Months 5 40 24 : :9 1L Esophageal, CPS ≥10 KEYNOTE-181 Pembro vs Chemo 1L HNSCC, CPS ≥20 KEYNOTE-048 Pembro vs EXTREME 1L HNSCC, CPS ≥1 KEYNOTE-048 Pembro vs EXTREME 1L NSCLC, TPS ≥50% KEYNOTE-042 Pembro vs Chemo 1L NSCLC, TPS ≥20% KEYNOTE-042 Pembro vs Chemo 1L NSCLC, TPS ≥1% KEYNOTE-042 Pembro vs Chemo 1L NSQ NSCLC, Any PD-L1 KEYNOTE-189 Pembro+ Pem/Platinum vs Placebo + Pem/Platinum Months Months : النسيا Months น Months : Nontha : 42 Months Months MERCK INVENTING FOR LIFE 1L Gastric, CPS ≥1 KEYNOTE-062 Pembro vs Chemo 1L Gastric, CPS ≥10 KEYNOTE-062 Pembro vs Chemo 2L HCC, Any PD-L1 KEYNOTĔ-240 Pembro vs Placebo 2L+HNSCC, Any PD-L1 KEYNOTE-040 Pembro vs SOC 1L HNSCC, Any PD-L1 KEYNOTE-048 Pembro vs EXTREME 1L HNSCC, CPS ≥1 KEYNOTE-048 Pembro + Platinum vs EXTREME 1L SQ NSCLC, Any PD-L1 KEYNOTE-407 Pembro + Carboplatin/Taxane vs Placebo + Carboplatin/Taxane Manths 12 16 42 20 30 36 Months Months Months لس 40- 10- 15 25 30 35 Months Months No. at Risk На : 188 Montha На # Dr. Roy Baynes H 50

View entire presentation